Denmark

Union Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Union Therapeutics A/s Completes Dosing of Healthy Volunteers with UNI911 (inhaled Niclosamide) for Covid-19

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 25, 2020

Details:

UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911. UNI911 utilizes an optimized salt form of niclosamide, an existing potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea.

Union Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

Danish Medicines Agency has approved initiation of a clinical study with an optimized salt form of niclosamide as a new treatment candidate for COVID-19.

Bavarian Nordic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine

Lead Product(s): MVA-BN-WEV

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 08, 2020

Details:

Data from the study showed that the vaccine was well tolerated and immunogenic across all dose groups.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Union Therapeutics

Union Therapeutics A/s Completes Dosing of Healthy Volunteers with UNI911 (inhaled Niclosamide) for Covid-19

Union Therapeutics

UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19

Bavarian Nordic

Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine